NVCR Share Price Performance
US$12.56
-17.84 (-58.68%)
69.6% undervalued intrinsic discount
US$41.25
Fair Value
Price US$12.56
AnalystHighTarget US$41.25
AnalystConsensusTarget US$24.93
AnalystLowTarget US$14.50
Fair ValueUS$41.25
Share Pricen/a
NovoCure Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 23 Fair Values set on narratives written by author
NVCR Community Narratives
AN
Fair Value US$41.25 69.6% undervalued intrinsic discount
TTFields Will Lead Oncological Advancements For Aging Populations
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$24.93 49.6% undervalued intrinsic discount
NVCR: Regulatory Wins And Clinical Milestones Will Drive Oncology Expansion
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value US$14.5 13.4% undervalued intrinsic discount
Regulatory Delays And Setbacks Will Restrict Adoption Yet Allow Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
TTFields Will Lead Oncological Advancements For Aging Populations
Key Takeaways Strong clinical adoption, regulatory tailwinds, and swift geographic expansion position NovoCure for underestimated market penetration and rapid revenue growth across multiple therapy lines. Operational improvements and device innovation boost patient adherence and margins, supporting a quicker path to profitability and resilience to macroeconomic shifts.Read more
32
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$41.25
69.6% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
11.05% p.a.
Profit Margin
12.91%
Future PE
54.7x
Price in 2028
US$52.45
NVCR: Regulatory Wins And Clinical Milestones Will Drive Oncology Expansion
Key Takeaways Expanding clinical validation, real-world adoption, and reimbursement advances are driving broader access, higher utilization, and long-term revenue stability for NovoCure. Ongoing launches, new indications, and development of combination therapies position the company for sustained international growth and competitive strength in the oncology market.Read more
203
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$24.93
49.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
11.73% p.a.
Profit Margin
13.38%
Future PE
31.39x
Price in 2028
US$31.79
Regulatory Delays And Setbacks Will Restrict Adoption Yet Allow Recovery
Key Takeaways Heavy reliance on Tumor Treating Fields exposes the company to revenue risks amid slow reimbursement and potential advances in competing therapies. High research and development costs, extended clinical timelines, and regulatory barriers could delay profitability and limit near-term market expansion.Read more
23
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$14.5
13.4% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
6.9% p.a.
Profit Margin
12.49%
Future PE
23.5x
Price in 2028
US$18.32
Trending Discussion
Recently Updated Narratives
AN
NVCR: Long-Term Pipeline And Margin Outlook Will Support Upside Potential
Fair Value: US$41.25 69.6% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
NVCR: Future Clinical Data Will Support Share Price Momentum Despite Cautious Outlook
Fair Value: US$24.93 49.6% undervalued intrinsic discount
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Delays And Setbacks Will Restrict Adoption Yet Allow Recovery
Fair Value: US$14.5 13.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
NovoCure Limited Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.59
- 75.53%
- -27.66%
- 221.3%
About NVCR
- Founded
- 2000
- Employees
- 1488
- CEO
- WebsiteView website
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
